Compare M&T Bank Corporation (MTB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Sanofi SA — how do they compare? M&T Bank Corporation trades at $237.67 (market cap $34.43B), while Sanofi SA trades at $42.7 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 3× M&T Bank Corporation's market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| MTB | SNY | |
|---|---|---|
Market Cap | $34.43B | $104.06B |
Sector | Financials | Health |
52-Week High | $254.09 | $52.34 |
52-Week Low | $178.63 | $41.33 |
Dividend Yield | 2.52% | 5.61% |
Enterprise Value | — | $124.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTB trades at $238.44, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q2 2026 EPS of $5.35 surpassing the $4.66 estimate. Revenue for 2025 reached $9.63 billion, with a net income margin of 30.85%. Recent news highlights participation in the Barclays Global Financial Services Conference and a declared quarterly dividend of $1.50 per share.
The outlook for MTB is supported by strong earnings performance and a consensus price target of $261.62, implying about 10% upside. However, risks include a negative net cash flow of -$2.01 billion in 2025 and elevated debt levels, with a debt-to-asset ratio of 6.09. Investor sentiment is mixed, with 31% of analysts rating it a buy but 60% recommending hold, reflecting caution amid macroeconomic pressures.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
